New Products
CLARISONIC OFFERS SONIC RADIANCE BRIGHTENING SOLUTION
Clarisonic introduced the Sonic Radiance Brightening Solution. According to the company, after using the new Sonic Radiance Brightening Solution, users can see an immediate 37 percent improvement in the texture of skin, 2.5x greater skin clarity after one week, and 10x greater improvement in hyperpigmentation after two weeks. The solution includes the Aria Cleansing Device with the new Radiance Brush Head for a gentle yet advanced, customizable cleanse, as well as two cleansers – Skin Illuminating Cleanser for morning use and the Skin Renewing Peel Wash for night to gently, evenly exfoliate and retexturize skin. With the new Brightening Activator Serum, Clarisonic makes its debut into leave-on treatments, responding to a growing consumer demand for amplified results by combining devices and formulations. Potent skin brightening ingredients ellagic acid and phenylethyl resorcinol combat discoloration, and also provide intense hydration to reveal a smoother, brighter complexion. Clarisonic.com
MEDICATED SOAP BARS LAUNCH AT SUMMER AAD
Ermis Labs has launched new medical soap bars containing ingredients to help relieve conditions such as acne, psoriasis, and atopic dermatitis. The bars include a 2% Pyrithione Zinc Seborrheic Dermatitis & Dandruff Treatment Bar, a 2% Salicylic Acne Treatment Exfoliating Cleansing Bar, a 1% Tolnaftate / 9% Sulfur Antifungal Medicated Bar, a 0.5% Coal Tar Psoriasis Medicated Bar and their 10% Benzoyl Peroxide Acne Treatment Cleansing Bar. All five bars are available through healthcare providers as physician-dispense and at independent pharmacies. Each Medicated Bar shares common ingredients including Vitamin A, Vitamin E and Shea Butter. All bars are manufactured in the United States and are made to a high density to provide longevity.Medicatedbars.com.
REVISION INTRODUCES NEW ENZYME CLEANSER
Revision Skincare's Papaya Enzyme Cleanser is an energizing facial cleanser containing unique enzyme and salicylic acid for all skin types. It also contains extract from the Papaya fruit, which helps to nourish the skin with vitamins and minerals. Revision.com.
VISCOT MEDICAL LAUNCHES WHITE E•Z REMOVABLE INK SKIN MARKERS
Viscot Medical recently introduced White E•Z Removable Ink to complement their existing green and red E•Z Removable Ink markers. E•Z Removable Ink comes off easily with an alcohol swab or water. E•Z Removable Ink eliminates the problem of patients walking out of the aesthetic procedure with ink marks on their face. It provides a clear, visible landmark for procedures. White E•Z Removable Ink is available as an economical mini marker in trial packs of six and containers of 30 markers. The white color ink offers a perfect complement to our existing green and red E•Z Removable Ink markers. viscot.com.
REGENICA SKINCARE SYSTEM GETS NEW LOOK
Suneva Medical, Inc. rebranded its Regenica product line, a skincare system formulated with Multipotent Resignaling Complex (MRCx) next generation growth factor technology. The green and silver color palette of the packaging closely aligns the brand's visual identity with its scientific foundation. The rebranded line is comprised of three products: Regenica Renew SPF 15, designed to protect skin from harmful UV rays while signaling skin's natural repair; Regenica Replenishing Crème to hydrate skin and reverse the signs of aging; and Regenica Repair Complex, which helps accelerate skin renewal. Regenica's MRCx next generation technology is a blend of physiologically balanced growth factors that are naturally secreted by human fibroblasts. These fibroblasts have been conditioned to act like younger cells resulting in younger, fresher growth factors. In a recent clinical study on Regenica, more than 94 percent of women saw an improvement in skin texture, tone, firmness, and the appearance of fine lines and wrinkles.regenica.com/physician/.
PURACAP PHARMACEUTICAL INTRODUCES EPICERAM 225g AIRLESS PUMP
PuraCap Pharmaceutical introduced the EpiCeram 225g Airless Pump. The airless pump is designed to give patients more EpiCeram to treat any size area of atopic dermatitis. The special dispensing system allows for more control, delivering EpiCeram consistently and precisely in a convenient to use, portable, pump action dispenser, according to the company. The EpiCeram Airless Pump also offers cost savings with BID dosing and a controlled release formulation that is long lasting. EpiCeram Controlled Release Skin Barrier Emulsion is a prescription product that helps to relieve the burning and itching associated with skin conditions such as atopic dermatitis/eczema. It is formulated with three essential lipids (ceramides, free fatty acids, and cholesterol) in a physiologically balanced ratio, which mimics the lipid concentration found in the skin. In addition, EpiCeram is designed with a patented, controlled release technology that delivers 24-hour barrier repair benefits with just a twice-daily application. A steroid-free topical formulation, EpiCeram is FDA-cleared for the treatment of atopic dermatitis.epiceram-us.com.
OBAGI360
The Obagi360 System is an all-encompassing skin care system designed to help proactively protect and improve the look of skin texture and tone. According to the company, the Obagi360 System is designed to address the facial skin care needs of younger patients, help prevent the visible signs of skin aging, provide a foundation for radiant, youthful-looking skin, and leave the skin clean, fresh, and glowing. The system includes an Exfoliating Cleanser, a Retinol 0.5%, and HydraFactor Broad Spectrum SPF 30. The cleanser is formulated with Linked-Papain (enzyme), two sizes of soft polyethylene beads, and high glycerin load to help clear clogged pores and thoroughly clean the skin. It's hypoallergenic and non-irritating. The retinol refines the appearance of skin texture and tone for a clearer looking skin with minimal irritation. It's formulated with entrapped retinol, shea butter, chamomile flower extract, bisabolol, and dipotassium glycyrrhizate, and is non-acnegenic and non-irritating. The HydraFactor is a dual-function moisturizer with soothing ingredients and broad-spectrum protection to help prevent skin damange casued by UVA/UVB rays. Key Ingredients include coenzyme Q10, vitamin E, Eperuline (anti-inflammatory), hydromanil, avobenzone 1%, Octinoxate 7.5%, Octisalate 5%, and Oxybenzone 5%. Obagi.com.
Therapeutic Update: Fungus
FDA APPROVES KERYDIN TO TREAT ONYCHOMYCOSIS
The FDA approved Anacor Pharmaceuticals' New Drug Application for Kerydin (tavaborole) topical solution, 5%, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes, as was reported in the July issue. For more about this, view a recent episode of DermWireTV. Visit http://bit.ly/1B9tvlp.
A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF LASER TREATMENT OF ONYCHOMYCOSIS
While antifungal drugs have been the mainstay of therapy for treating onychomycosis, laser technologies have been introduced in recent years as an effective, alternative treatment option that avoids the disadvantages associated with systemic and topical drug therapies. A recent study was conducted to to review published evidence regarding the effectiveness of laser technologies for treating onychomycosis. A systematic literature search of published papers indexed on Pubmed and Web of Science was conducted in June 2014 for original, published research. The primary outcome measures for efficacy were mycological cure and clearance of the affected nail. According to the published results, this review returned 12 eligible published studies evaluating the use of lasers in the treatment of onychomycosis—two were randomized controlled trials, four were comparative design studies (with no placebo/control groups), and six were case series. Researchers found that “the level of evidence was generally low level reflecting predominantly small sample size and lack of control groups.” They also found the results of the studies were conflicting, follow-up periods used in the studies were typically short, and that many studies excluded patients with severe or dystrophic onychomycosis.
The authors concluded, “The evidence pertaining to the effectiveness of laser treatment of onychomycosis is limited and of poor methodological quality. Future studies using randomized controlled trial designs with larger study populations and clear procedures are required to permit a full evaluation of this emerging technology.”
J Foot Ankle Res. 2014 Jul 27;7:34.
ASSESSING TERBINAFINE EFFICACY IN AFFECTED ONYCHOMYCOTIC TOENAILS
A case series study based on a single-center cohort was conducted to evaluate the efficacy of terbinafine in all affected onychomycotic toenails and the differences in mycological, clinical, and complete cure rate between affected onychomycotic toenails.
Eur Acad Dermatol Venereol. 2014 Jul 30.
[Epub ahead of print]
DIFFERENTIATING TINEA CAPITIS FROM ALOPECIA AREATA IN PEDIATRIC PATIENTS
To compare the different trichoscopic features of tinea capitis and alopecia areata in pediatric patients, researchers conducted a study with 40 patients—20 patients with tinea capitis and 20 patients with alopecia areata. Patients were exposed to clinical examination, laboratory investigations (10% KOH and fungal culture), and trichoscope examination. The study found that comma shaped hairs, corkscrew hairs, and zigzag shaped hairs are the diagnostic trichoscopic features of tinea capitis. In alopecia areata patients, the most trichoscopic specific features were yellow dots, exclamation mark, and short vellus hairs. “Trichoscopy can be used as a noninvasive tool for rapid diagnosis of tinea capitis and alopecia areata in pediatric patients,” the authors concluded.
Dermatol Res Pract. 2014;2014:848763. Epub 2014 Jun 16.
EFFICACY AND SAFETY OF ONCE-DAILY LULICONAZOLE 1% CREAM
In a Phase III study to assess the safety and efficacy of luliconazole cream 1% in patients with tinea pedis, 321 male and female patients 12 years and older with tinea pedis and eligible for modified intent-to-treat analysis were randomized 1:1 to receive luliconazole cream 1% (n=159) or vehicle (n=162) once daily for 14 days. Efficacy was evaluated at days 28 and 42 based on clinical signs (erythema, scaling, pruritus) and mycology (KOH, fungal culture). Complete clearance at day 42 was achieved in 26.4 percent (28/106) of patients treated with luliconazole cream 1% compared with 1.9 percent (2/103) of patients treated with vehicle. Similar safety profiles were obtained for luliconazole cream 1% and vehicle. Authors noted that this study was limited because it was conducted in a relatively small population under controlled clinical trial conditions, but concluded thatl uliconazole cream 1% applied once daily for 14 days is well tolerated and more effective than vehicle in patients with tinea pedis.
J Drugs Dermatol. 2014 Jul 1;13(7):838-46.
ECONAZOLE NITRATE FOAM 1% FOR TREATMENT OF TINEA PEDIS
To evaluate econazole nitrate foam 1% versus foam vehicle for treatment of interdigital tinea pedis, two randomized, double-blind, parallel-group, vehicle-controlled, multicenter studies enrolled males and females 12 years and older with a clinical diagnosis of interdigital tinea pedis and baseline fungal culture positive for a dermatophyte. Subjects applied econazole nitrate foam 1% (n=246) or foam vehicle (n=249) once daily for four weeks. Complete cure rate (negative KOH, negative fungal culture, complete resolution of all signs and symptoms) at day 43 was 24.3 percent for econazole nitrate foam 1% vs 3.6 percent for foam vehicle. In addition, higher rates of mycologic cure (67.6 percent vs 16.9 percent) and effective treatment (48.6 percent vs 10.8 percent) were observed with econazole nitrate foam 1% versus the foam vehicle. There were few adverse events—nasopharyngitis and headache were experienced by less than one percent of patients. No serious adverse events were reported for econazole nitrate foam 1%. Researchers found that econazole nitrate foam 1% was safe and well tolerated with a safety profile comparable with the foam vehicle. “Econazole nitrate foam 1% presents a novel alternative for the management of tinea pedis,” the authors noted.
J Drugs Dermatol. 2014 Jul 1;13(7):803-8.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- New Products
New Products
- New Products
New Products
- New Products
Currents: Therapeutic Advances
- New Products
New in My Practice: OTC/New Products